Search research articles
Contact Us
Filters
Showing results (11-20 of 139) with videos related to
Page
of 14
Sort By:
Health Affairs (Project Hope)
|
December 6, 2021
Raising Medicaid Rebates For Drugs With Accelerated Approval
Benjamin N Rome, Aaron S Kesselheim
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 21, 2019
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis
Benjamin N Rome, Aaron S Kesselheim
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 7, 2023
Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups
Benjamin N Rome, Aaron S Kesselheim
The New England Journal of Medicine
|
February 18, 2026
The Growing Success of Medicare Drug-Price Negotiation
Benjamin N Rome, Aaron S Kesselheim
JAMA
|
July 28, 2025
Lowering Drug Prices in the US-Look Within, Not Abroad
Suhas Gondi, Irene Papanicolas, Benjamin N Rome
Chest
|
August 8, 2022
The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
Liam Bendicksen, Aaron S Kesselheim, Benjamin N Rome
JAMA
|
June 27, 2024
Misaligned Pharmacy Incentives in Value-Based Care
Nina Jain, Benjamin N Rome, Mallika L Mendu
Journal of Managed Care & Specialty Pharmacy
|
October 31, 2025
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiation
John Kim, Aaron S Kesselheim, Benjamin N Rome
The New England Journal of Medicine
|
December 10, 2025
Generic Liraglutide - Overlooked but Not Forgotten
Suhas Gondi, Aaron S Kesselheim, Benjamin N Rome
BMJ (Clinical Research Ed.)
|
September 9, 2021
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study
Bishal Gyawali, Benjamin N Rome, Aaron S Kesselheim
Page
of 14
Search research articles
Search
Showing results (11-20 of 139) with videos related to
Sort By:
Page
of 14
Health Affairs (Project Hope)
|
December 6, 2021
Raising Medicaid Rebates For Drugs With Accelerated Approval
Benjamin N Rome, Aaron S Kesselheim
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 21, 2019
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis
Benjamin N Rome, Aaron S Kesselheim
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 7, 2023
Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups
Benjamin N Rome, Aaron S Kesselheim
The New England Journal of Medicine
|
February 18, 2026
The Growing Success of Medicare Drug-Price Negotiation
Benjamin N Rome, Aaron S Kesselheim
JAMA
|
July 28, 2025
Lowering Drug Prices in the US-Look Within, Not Abroad
Suhas Gondi, Irene Papanicolas, Benjamin N Rome
Chest
|
August 8, 2022
The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
Liam Bendicksen, Aaron S Kesselheim, Benjamin N Rome
JAMA
|
June 27, 2024
Misaligned Pharmacy Incentives in Value-Based Care
Nina Jain, Benjamin N Rome, Mallika L Mendu
Journal of Managed Care & Specialty Pharmacy
|
October 31, 2025
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiation
John Kim, Aaron S Kesselheim, Benjamin N Rome
The New England Journal of Medicine
|
December 10, 2025
Generic Liraglutide - Overlooked but Not Forgotten
Suhas Gondi, Aaron S Kesselheim, Benjamin N Rome
BMJ (Clinical Research Ed.)
|
September 9, 2021
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study
Bishal Gyawali, Benjamin N Rome, Aaron S Kesselheim
Page
of 14